Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.52 |
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8954810 | 1.00 | DPP7 (0.52) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL6164203 | 1.00 | DPP7 (0.52) | DPP7DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL29656973 | 0.99 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3745993 | 0.99 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL2820818 | 0.99 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL8125273 | 0.99 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL7404834 | 0.88 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL7403825 | 0.88 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL7404836 | 0.88 | DPP7 (0.51) | DPP7DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL7403820 | 0.86 | DPP7 (0.50) | DPP7DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169676-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | WASHINGTON UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2016144654-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2016-09-15 | — | — | WO | disclosed |
| US-8569313-B2 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569313-B2 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2132174-B1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MEDICINES CO LEIPZIG GMBH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-6624169-B1 | 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases targeting lymphocytes and for treating disorders of the lymphatic tissue, in particular lymphomas. | WILEX BIOTECHNOLOGY GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| US-20030013723-A1 | Antitumor agents | WILEX AG | 2003-01-16 | — | — | US | disclosed |
| US-6489331-B1 | A CONDENSED PURINE DERIVATIVE AS AN ACTIVE INGREDIENT AS AN ENHANCER OF INSULIN SECRETION AND A MEDICAMENT FOR THE TREATMENT OF DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-5518735-A | ANTICOAGULANTS ADMINISTERED BY MOUTH | PENTAPHARM AG (CH) | 1996-05-21 | — | — | US | disclosed |
| EP-0511347-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | Pentapharm A.G. (CH) | 1992-11-04 | — | — | EP | disclosed |
| WO-1992008709-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | PENTAPHARM AG (CH) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MMP7, DNPEP, METAP1 | DPP7 17/4885DPP4 22/4885FAP 6/4885 |
| US-20030013723-A1 | Antitumor agents | DNPEP, PLAU, ENPEP | DPP7 311/4885DPP4 399/4885FAP 17/4885 |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | HDGF, MMP7, HGF | DPP7 354/4885DPP4 682/4885FAP 147/4885 |
| US-20220169676-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | HDGF, MMP7, HGF | DPP7 354/4885DPP4 682/4885FAP 147/4885 |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | DPP7 452/4885DPP4 540/4885FAP 138/4885 |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | HDGF, MMP7, HGF | DPP7 354/4885DPP4 682/4885FAP 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.